Does the media favor IMVT or RXRX?

In the previous week, Immunovant had 1 more articles in the media than Recursion Pharmaceuticals. MarketBeat recorded 10 mentions for Immunovant and 9 mentions for Recursion Pharmaceuticals. Recursion Pharmaceuticals' average media sentiment score of 0.74 beat Immunovant's score of 0.60 indicating that Recursion Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 4 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Recursion Pharmaceuticals 2 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to RXRX or RYTM?

In the previous week, Recursion Pharmaceuticals had 5 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 9 mentions for Recursion Pharmaceuticals and 4 mentions for Rhythm Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 1.14 beat Recursion Pharmaceuticals' score of 0.74 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Recursion Pharmaceuticals 2 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rhythm Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to RXRX or MIRM?

In the previous week, Recursion Pharmaceuticals had 3 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 9 mentions for Recursion Pharmaceuticals and 6 mentions for Mirum Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 1.53 beat Recursion Pharmaceuticals' score of 0.74 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Recursion Pharmaceuticals 2 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mirum Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor SYRE or RXRX?

In the previous week, Recursion Pharmaceuticals had 2 more articles in the media than Spyre Therapeutics. MarketBeat recorded 9 mentions for Recursion Pharmaceuticals and 7 mentions for Spyre Therapeutics. Spyre Therapeutics' average media sentiment score of 0.85 beat Recursion Pharmaceuticals' score of 0.74 indicating that Spyre Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyre Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Recursion Pharmaceuticals 2 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer LNTH or RXRX?

In the previous week, Recursion Pharmaceuticals had 2 more articles in the media than Lantheus. MarketBeat recorded 9 mentions for Recursion Pharmaceuticals and 7 mentions for Lantheus. Lantheus' average media sentiment score of 0.76 beat Recursion Pharmaceuticals' score of 0.74 indicating that Lantheus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Recursion Pharmaceuticals 2 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Recursion Pharmaceuticals (RXRX) Competitors

$3.02 -0.29 (-8.76%)

Closing price 07/16/2026 04:00 PM Eastern

Extended Trading

$3.02 0.00 (-0.03%)

As of 07/16/2026 07:59 PM Eastern

Compare

RXRX vs. IMVT, RYTM, MIRM, SYRE, and LNTH

Should you buy Recursion Pharmaceuticals stock or one of its competitors? MarketBeat compares Recursion Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Recursion Pharmaceuticals include Immunovant (IMVT), Rhythm Pharmaceuticals (RYTM), Mirum Pharmaceuticals (MIRM), Spyre Therapeutics (SYRE), and Lantheus (LNTH). These companies are all part of the "pharmaceutical products" industry.

How does Recursion Pharmaceuticals compare to Immunovant?

Immunovant (NASDAQ:IMVT) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, institutional ownership, risk, profitability and earnings.

Immunovant has a net margin of 0.00% compared to Recursion Pharmaceuticals' net margin of -842.95%. Recursion Pharmaceuticals' return on equity of -54.33% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-65.66%	-59.88%
Recursion Pharmaceuticals	-842.95%	-54.33%	-40.60%

47.1% of Immunovant shares are owned by institutional investors. Comparatively, 89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. 1.8% of Immunovant shares are owned by insiders. Comparatively, 6.7% of Recursion Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Immunovant has higher earnings, but lower revenue than Recursion Pharmaceuticals. Immunovant is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.78	N/A
Recursion Pharmaceuticals	$74.68M	21.43	-$644.76M	-$1.20	N/A

Immunovant has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market. Comparatively, Recursion Pharmaceuticals has a beta of 1, indicating that its stock price has a similar volatility profile to the broader market.

Immunovant currently has a consensus price target of $39.70, indicating a potential upside of 1.90%. Recursion Pharmaceuticals has a consensus price target of $8.10, indicating a potential upside of 168.21%. Given Recursion Pharmaceuticals' higher probable upside, analysts clearly believe Recursion Pharmaceuticals is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, Immunovant had 1 more articles in the media than Recursion Pharmaceuticals. MarketBeat recorded 10 mentions for Immunovant and 9 mentions for Recursion Pharmaceuticals. Recursion Pharmaceuticals' average media sentiment score of 0.74 beat Immunovant's score of 0.60 indicating that Recursion Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	4 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Recursion Pharmaceuticals	2 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Recursion Pharmaceuticals beats Immunovant on 10 of the 15 factors compared between the two stocks.

How does Recursion Pharmaceuticals compare to Rhythm Pharmaceuticals?

Recursion Pharmaceuticals (NASDAQ:RXRX) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk.

In the previous week, Recursion Pharmaceuticals had 5 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 9 mentions for Recursion Pharmaceuticals and 4 mentions for Rhythm Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 1.14 beat Recursion Pharmaceuticals' score of 0.74 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Recursion Pharmaceuticals	2 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rhythm Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rhythm Pharmaceuticals has a net margin of -93.33% compared to Recursion Pharmaceuticals' net margin of -842.95%. Recursion Pharmaceuticals' return on equity of -54.33% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Recursion Pharmaceuticals	-842.95%	-54.33%	-40.60%
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%

Rhythm Pharmaceuticals has higher revenue and earnings than Recursion Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Recursion Pharmaceuticals	$74.68M	21.43	-$644.76M	-$1.20	N/A
Rhythm Pharmaceuticals	$189.76M	38.31	-$196.54M	-$3.13	N/A

Recursion Pharmaceuticals currently has a consensus target price of $8.10, suggesting a potential upside of 168.21%. Rhythm Pharmaceuticals has a consensus target price of $138.29, suggesting a potential upside of 30.35%. Given Recursion Pharmaceuticals' higher probable upside, equities research analysts clearly believe Recursion Pharmaceuticals is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.76

89.1% of Recursion Pharmaceuticals shares are held by institutional investors. 6.7% of Recursion Pharmaceuticals shares are held by insiders. Comparatively, 5.9% of Rhythm Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Recursion Pharmaceuticals has a beta of 1, indicating that its stock price has a similar volatility profile to the broader market.Comparatively, Rhythm Pharmaceuticals has a beta of 1.88, indicating that its stock price is 88% more volatile than the broader market.

Summary

Recursion Pharmaceuticals and Rhythm Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Recursion Pharmaceuticals compare to Mirum Pharmaceuticals?

Recursion Pharmaceuticals (NASDAQ:RXRX) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, media sentiment, risk, dividends and valuation.

Mirum Pharmaceuticals has higher revenue and earnings than Recursion Pharmaceuticals. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Recursion Pharmaceuticals	$74.68M	21.43	-$644.76M	-$1.20	N/A
Mirum Pharmaceuticals	$521.31M	13.73	-$23.36M	-$13.61	N/A

89.1% of Recursion Pharmaceuticals shares are held by institutional investors. 6.7% of Recursion Pharmaceuticals shares are held by company insiders. Comparatively, 8.3% of Mirum Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Recursion Pharmaceuticals had 3 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 9 mentions for Recursion Pharmaceuticals and 6 mentions for Mirum Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 1.53 beat Recursion Pharmaceuticals' score of 0.74 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Recursion Pharmaceuticals	2 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mirum Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Recursion Pharmaceuticals presently has a consensus price target of $8.10, suggesting a potential upside of 168.21%. Mirum Pharmaceuticals has a consensus price target of $143.40, suggesting a potential upside of 22.19%. Given Recursion Pharmaceuticals' higher possible upside, equities research analysts plainly believe Recursion Pharmaceuticals is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

Recursion Pharmaceuticals has a beta of 1, indicating that its stock price has a similar volatility profile to the broader market.Comparatively, Mirum Pharmaceuticals has a beta of 0.48, indicating that its stock price is 52% less volatile than the broader market.

Mirum Pharmaceuticals has a net margin of -140.24% compared to Recursion Pharmaceuticals' net margin of -842.95%. Mirum Pharmaceuticals' return on equity of -11.28% beat Recursion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Recursion Pharmaceuticals	-842.95%	-54.33%	-40.60%
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%

Summary

Mirum Pharmaceuticals beats Recursion Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Recursion Pharmaceuticals compare to Spyre Therapeutics?

Spyre Therapeutics (NASDAQ:SYRE) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, profitability, valuation, dividends and risk.

In the previous week, Recursion Pharmaceuticals had 2 more articles in the media than Spyre Therapeutics. MarketBeat recorded 9 mentions for Recursion Pharmaceuticals and 7 mentions for Spyre Therapeutics. Spyre Therapeutics' average media sentiment score of 0.85 beat Recursion Pharmaceuticals' score of 0.74 indicating that Spyre Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyre Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Recursion Pharmaceuticals	2 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Spyre Therapeutics has a net margin of 0.00% compared to Recursion Pharmaceuticals' net margin of -842.95%. Spyre Therapeutics' return on equity of -42.88% beat Recursion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-42.88%	-27.76%
Recursion Pharmaceuticals	-842.95%	-54.33%	-40.60%

Spyre Therapeutics currently has a consensus target price of $101.42, indicating a potential upside of 7.75%. Recursion Pharmaceuticals has a consensus target price of $8.10, indicating a potential upside of 168.21%. Given Recursion Pharmaceuticals' higher probable upside, analysts plainly believe Recursion Pharmaceuticals is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Spyre Therapeutics has a beta of 3.02, meaning that its share price is 202% more volatile than the broader market. Comparatively, Recursion Pharmaceuticals has a beta of 1, meaning that its share price has a similar volatility profile to the broader market.

80.4% of Spyre Therapeutics shares are held by institutional investors. Comparatively, 89.1% of Recursion Pharmaceuticals shares are held by institutional investors. 15.7% of Spyre Therapeutics shares are held by company insiders. Comparatively, 6.7% of Recursion Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Spyre Therapeutics has higher earnings, but lower revenue than Recursion Pharmaceuticals. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyre Therapeutics	$890K	9,299.90	-$155.20M	-$2.08	N/A
Recursion Pharmaceuticals	$74.68M	21.43	-$644.76M	-$1.20	N/A

Summary

Spyre Therapeutics beats Recursion Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Recursion Pharmaceuticals compare to Lantheus?

Lantheus (NASDAQ:LNTH) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings, media sentiment and valuation.

99.1% of Lantheus shares are held by institutional investors. Comparatively, 89.1% of Recursion Pharmaceuticals shares are held by institutional investors. 1.7% of Lantheus shares are held by insiders. Comparatively, 6.7% of Recursion Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Lantheus has a net margin of 18.05% compared to Recursion Pharmaceuticals' net margin of -842.95%. Lantheus' return on equity of 29.32% beat Recursion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	18.05%	29.32%	15.00%
Recursion Pharmaceuticals	-842.95%	-54.33%	-40.60%

Lantheus presently has a consensus price target of $110.43, suggesting a potential upside of 5.06%. Recursion Pharmaceuticals has a consensus price target of $8.10, suggesting a potential upside of 168.21%. Given Recursion Pharmaceuticals' higher probable upside, analysts clearly believe Recursion Pharmaceuticals is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Lantheus has higher revenue and earnings than Recursion Pharmaceuticals. Recursion Pharmaceuticals is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.54B	4.44	$233.56M	$4.15	25.33
Recursion Pharmaceuticals	$74.68M	21.43	-$644.76M	-$1.20	N/A

Lantheus has a beta of -0.06, indicating that its share price is 106% less volatile than the broader market. Comparatively, Recursion Pharmaceuticals has a beta of 1, indicating that its share price has a similar volatility profile to the broader market.

In the previous week, Recursion Pharmaceuticals had 2 more articles in the media than Lantheus. MarketBeat recorded 9 mentions for Recursion Pharmaceuticals and 7 mentions for Lantheus. Lantheus' average media sentiment score of 0.76 beat Recursion Pharmaceuticals' score of 0.74 indicating that Lantheus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Recursion Pharmaceuticals	2 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Lantheus beats Recursion Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

Get Recursion Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RXRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RXRX vs. The Competition

Export

Metric	Recursion Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.75B	$3.03B	$6.96B	$12.67B
Dividend Yield	N/A	2.09%	2.68%	8.87%
P/E Ratio	-2.52	19.86	27.18	24.05
Price / Sales	21.43	804.27	577.75	112.08
Price / Cash	N/A	56.84	49.25	59.89
Price / Book	1.41	4.23	10.78	6.23
Net Income	-$644.76M	$65.46M	$3.59B	$331.94M
7 Day Performance	-15.17%	-2.95%	-1.92%	-1.65%
1 Month Performance	-2.89%	0.82%	2.24%	-1.03%
1 Year Performance	-45.29%	16.53%	23.85%	17.10%

Recursion Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RXRX Recursion Pharmaceuticals	3.3766 of 5 stars	$3.02 -8.8%	$8.10 +168.2%	-44.0%	$1.75B	$74.68M	N/A	400
IMVT Immunovant	2.0319 of 5 stars	$38.79 flat	$39.70 +2.3%	+118.8%	$7.96B	N/A	N/A	120
RYTM Rhythm Pharmaceuticals	3.0353 of 5 stars	$114.17 flat	$133.13 +16.6%	+16.0%	$7.82B	$189.76M	N/A	140	Positive News
MIRM Mirum Pharmaceuticals	3.2143 of 5 stars	$125.59 flat	$143.00 +13.9%	+122.3%	$7.66B	$521.31M	N/A	140	Gap Down
SYRE Spyre Therapeutics	1.7964 of 5 stars	$86.63 flat	$95.83 +10.6%	+481.0%	$7.62B	$890K	N/A	73

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RXRX) was last updated on 7/17/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Recursion Pharmaceuticals (RXRX) Competitors

RXRX vs. IMVT, RYTM, MIRM, SYRE, and LNTH

How does Recursion Pharmaceuticals compare to Immunovant?

Summary

How does Recursion Pharmaceuticals compare to Rhythm Pharmaceuticals?

Summary

How does Recursion Pharmaceuticals compare to Mirum Pharmaceuticals?

Summary

How does Recursion Pharmaceuticals compare to Spyre Therapeutics?

Summary

How does Recursion Pharmaceuticals compare to Lantheus?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RXRX vs. The Competition

Recursion Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Recursion Pharmaceuticals (RXRX) Competitors

RXRX vs. IMVT, RYTM, MIRM, SYRE, and LNTH

How does Recursion Pharmaceuticals compare to Immunovant?

Is IMVT or RXRX more profitable?

Do insiders & institutionals believe in IMVT or RXRX?

Which has higher valuation & earnings, IMVT or RXRX?

Which has more risk & volatility, IMVT or RXRX?

Do analysts recommend IMVT or RXRX?

Does the media favor IMVT or RXRX?

Summary

How does Recursion Pharmaceuticals compare to Rhythm Pharmaceuticals?

Does the media refer more to RXRX or RYTM?

Is RXRX or RYTM more profitable?

Which has stronger valuation & earnings, RXRX or RYTM?

Do analysts rate RXRX or RYTM?

Do institutionals and insiders have more ownership in RXRX or RYTM?

Which has more volatility and risk, RXRX or RYTM?

Summary

How does Recursion Pharmaceuticals compare to Mirum Pharmaceuticals?

Which has better earnings and valuation, RXRX or MIRM?

Do institutionals & insiders have more ownership in RXRX or MIRM?

Does the media refer more to RXRX or MIRM?

Do analysts rate RXRX or MIRM?

Which has more risk & volatility, RXRX or MIRM?

Is RXRX or MIRM more profitable?

Summary

How does Recursion Pharmaceuticals compare to Spyre Therapeutics?

Does the media favor SYRE or RXRX?

Is SYRE or RXRX more profitable?

Do analysts rate SYRE or RXRX?

Which has more volatility and risk, SYRE or RXRX?

Do insiders and institutionals believe in SYRE or RXRX?

Which has higher valuation and earnings, SYRE or RXRX?

Summary

How does Recursion Pharmaceuticals compare to Lantheus?

Do institutionals and insiders have more ownership in LNTH or RXRX?

Is LNTH or RXRX more profitable?

Do analysts recommend LNTH or RXRX?

Which has higher earnings and valuation, LNTH or RXRX?

Which has more risk and volatility, LNTH or RXRX?

Does the media prefer LNTH or RXRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RXRX vs. The Competition

Recursion Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools